The metabolic syndrome: Linking oxidative stress and inflammation to obesity, type 2 diabetes, and the syndrome

Drug Development Research

Volumn 67, Issue 7, 2006, Pages 619-626

  Dandona, Paresh ^a   Ghanim, Husam ^a   Mohanty, Priya ^a   Chaudhuri, Ajay ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Inflammation; Metabolic syndrome; Obesity; Oxidative stress

Indexed keywords

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; FOOD INTAKE; HORMONE RESPONSE; HUMAN; HYPERINSULINEMIA; HYPOTHESIS; INFLAMMATION; INSULIN RESISTANCE; MACRONUTRIENT; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

EID: 33845203979     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20137     Document Type: Conference Paper

References (56)

1. Aljada A, Ghanim H, Assian E, Dandona P. 2002a. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism 51:487-491.
2. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. 2002b. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 87:1419-1422.
3. Aljada A, Mohanty P, Ghanim H, Abdo T, Tripathy D, Chaudhuri A, Dandona P. 2004, Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 79:682-690.
4. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. 2001. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389.
5. Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A, Calieri J, Hoffmeyer D, Tufail S, Ghanim H, Aljada A, Dandona P. 2004. Anti-inflammatory and pro-fibrinolytic effect of insulin in acute ST-elevation myocardial infarction. Circulation 109:849-854.
6. Chaudhuri A, Janicke D, Wilson MF, Ghanim H, Aljada A, Dandona P. 2005. Free fatty acid suppressive, Pro- MMP-1 lowering and cardioprotective effect of insulin in STEMI. 87th Annual Scientific Session of Endocrine Society.
7. Cheung NW, Wong WV, McLean M. 2006. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 29:765-770.
8. Crook MA, Tutt P, Pickup JC. 1993. Elevated serum sialic acid concentration in NIDDM and its relationship to blood pressure and retinopathy. Diabetes Care 16:57-60.
9. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. 1998. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907-2910.
10. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. 2001a. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257-3265.
11. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, Prabhala A, Afzal A, Garg R. 2001b. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 86:355-362.
12. Dandona P, Mohanty P, Hamouda W, Ghanim H, Aljada A, Garg R, Kumar V. 2001c. Inhibitory effect of a two day fast on reactive oxygen species (ROS) generation by leucocytes and plasma orthotyrosine and meta-tyrosine concentrations. J Clin Endocrinol Metab 86:2899-2902.
13. Dhindsa S, Tripathy D, Sanalkumar N, Ravishankar S, Ghanim H, Aljada A, Dandona P. 2005. Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment. J Clin Endocrinol Metab 90:5058-5063.
14. Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G. 2000. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults: the ARIC study. Atherosclerosis Risk in Communities. Obes Res 8:279-286.
15. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. 2003. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799-1805.
16. Engstrom G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgarde F. 2003. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 52:2097-2101.
17. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. 2002. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067-2072.
18. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. 2003. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 88:2714-2718.
19. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, Dandona P. 2000. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 36:430-435.
20. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P. 2001. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential anti-atherosclerotic effect in the obese. J Clin Endocrinol Metab 86:1306-1312.
21. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. 2004. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110:1564-1571.
22. Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P, Dandona P. 2006. Low dose rosiglitazone exerts an anti-inflammatory effect with an increase in adiponectin independently of free fatty acid (FFA) fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab.
23. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. 1999. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 48:437-441.
24. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684.
25. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. 1999. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19:1986-1991.
26. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. 2002. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016-2021.
27. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91.
28. Hotamisligil GS, Budavari A, Caro JF, Atkinson RL, Spiegelman BM. 1994. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94:1543-1549.
29. Hotamisligil GS, Arner P, Murray D, Spiegelman BM. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415.
30. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. 2003. Plasmino gen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575-1579.
31. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. 2003. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 100:9090-9095.
32. Krljanac G, Vasiljevic Z, Radovanovic M, Stankovic G, Milic N, Stefanovic B, Kostic J, Mitrovic P, Radovanovic N, Dragovic M, Marinkovic J, Karadzic A. 2005. Effects of glucose-insulin-potassium infusion on st-elevation myocardial infarction in patients treated with thrombolytic therapy. Am J Cardiol 96:1053-1058.
33. Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M. 2003. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52:1872-1876.
34. La Cava A, Alviggi C, Matarese G. 2004. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 82:4-11.
35. Lemieux I, Pascot A, Prud'homme D, Aimeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP. 2001. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 21:961-967.
36. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. 1996. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 93:106-110.
37. Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE, Griveas I, Katsilambros N, Flier JS. 1997. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. J Clin Endocrinol Metab 82:3408-3413.
38. Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, Zappacosta S. 2002. Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol 23:182-187.
39. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L. 2005. Effetct of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Jama 293:437-446.
40. Miller GE, Freedland KE, Carney RM, Stetler CA, Banks WA. 2003. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun 17:276-285.
41. Mohamed-Ail V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. 1997. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200.
42. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. 2000. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970-2973.
43. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. 2004. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89:2728-2735.
44. Nakata M, Yada T, Soejim N, Maruyama I. 1999. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 48:426-429.
45. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. 1996. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885.
46. Padgett DA, Glaser R. 2003. How stress influences the immune response. Trends Immunol 24:444-448.
47. Pickup JC, Mattock MB, Chusney GD, Burt D. 1997. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292.
48. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334.
49. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. 2003. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 23:650-655.
50. Ross R. 1999. Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126.
51. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. 1999. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353:1649-1652.
52. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. 2002. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399.
53. Senn JJ, Klover PJ, Nowak IA, Mooney RA. 2003. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740-13746.
54. Surwi RS, Schneider MS, Feinglos MN. 1992. Stress and diabetes mellitus. Diabetes Care 15:1413-1422.
55. Visser L, Zuurbier CJ, Hoek FJ, Opmeer BC, de Jonge E, de Mol BA, van Wezel HB. 2005. Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: effects on inflammatory response during coronary artery surgery. Br J Anaesth 95:448-457.
56. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. 1999. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978.